Anish M. John - 15 Aug 2022 Form 4 Insider Report for Oncocyte Corp (OCX)

Role
Chief Financial Officer
Signature
/s/ Anish John
Issuer symbol
OCX
Transactions as of
15 Aug 2022
Net transactions value
$0
Form type
4
Filing time
17 Aug 2022, 20:19:44 UTC
Previous filing
13 Jun 2022
Next filing
19 Jan 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OCX Common Stock, no par value Award $0 +150,000 $0.000000 150,000 15 Aug 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OCX Option to Purchase Common Stock Award $0 +100,000 $0.000000 100,000 15 Aug 2022 Common Stock 100,000 $0.9700 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Restricted Stock Units shall vest on January 1, 2024 based on the achievement of a pre-determined financial objective related to the Issuer's available cash.
F2 25% of the options will become exercisable after one year of continuous service from the effective date of grant, and the balance will become exercisable in 36 equal monthly installments commencing one year after the date of grant subject to continuous service through the applicable vesting date.